Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 300, Issue 5, 2011, Pages

  Chan, Hui Min ^a   Jain, Ritesh ^a   Ahrén, Bo ^b   Pacini, Giovanni ^c   D'Argenio, David Z ^a  

^a University of Southern California   (United States)

^b LUND UNIVERSITY   (Sweden)

^c CNR   (Italy)

Author keywords

Glucose tolerance; Insulin secretion; Insulin sensitivity; Intravenous glucose test; Population analysis

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE TOLERANCE; IN VIVO STUDY; INFORMATION PROCESSING; INSULIN RELEASE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, BIOLOGICAL;

EID: 79955754193     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00687.2010     Document Type: Article

References (36)

1. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long-acting GLP-1 derivative. Eur J Pharm Sci 19: 141-150, 2003.
2. Ahrén B, Pacini G. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol Endocrinol Metab 277: E996-E1004, 1999.
3. Ahrén B, Holst JJ, Mårtensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404: 239-245, 2000.
4. Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 150: 97-104, 2004.
5. Ahrén B, Schmitz OO. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36: 867-887, 2004.
6. Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin and saxagliptin- diabetes control and potential adverse events. Best Pract Clin Endocrinol Metab 23: 487-498, 2009.
7. Barg S, Eliasson L, Rorsman P. A subset of 50 secretory granules in close contact with L-type Ca2 channels accounts for first phase insulin secretion in mouse beta-cells. Diabetes 51 Suppl 1: S74-S82, 2002.
8. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653-2659, 2004.
9. Bruss ML, Black AL. Enzymatic microdetermination of glycogen. Anal Biochem 84: 309-312, 1978.
10. Caumo A, Luzi L. First phase insulin secretion: does it exist in real life? Consideration on shape and function. Am J Physiol Endocrinol Metab 287: E371-E385, 2004.
11. Dachicourt N, Serradas P, Bailbe D, Kergoat M, Doare L, Portha B. Glucagon-like peptide-1 (7-36)-amide confers glucose sensitivity to previously glucose-incompetent - cells in diabetic rats: in vivo and in vitro studies. J Endocrinol 155: 369-376, 1997.
12. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263-2266, 1994.
13. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles, CA: Biomedical Simulations Resource, 2009.
14. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data. London: Chapman and Hill, 1995.
15. De Ore K, Greig NH, Holloway HW, Wang Y, Perfetti R, Egan JM. The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test. J Gerontol A Biol Sci Med Sci 52: B245-B249, 1997.
16. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res 56: 377-399, 2001.
17. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546-593, 2007.
18. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 30: 609-624, 2010.
19. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90: 5991-5997, 2005.
20. Hendrick GK, Gjinovci A, Baxter LA, Mojsov S, Wollheim CB, Habener JF, Weir GC. Glucagon-like peptide-1-(7-37) suppresses hyperglycemia in rats. Metabolism 42: 1-6, 1993.
21. Hou JC, Min L, Pessin JE. Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm 80: 473-506, 2009.
22. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergmann RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
23. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
24. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36: 197-209, 2005.
25. Mager DE, Abernethy DR, Egan JM, Elahi D. Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 311: 830-835, 2004.
26. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87: 1239-1246, 2002.
27. Pacini G, Thomaseth K, Ahrén B. Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 281: E693-E703, 2001.
28. Pacini G. The hyperbolic equilibrium between insulin sensitivity and secretion. Nutr Metab Cardiovasc Dis 16 Suppl 1: S22-S27, 2006.
29. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26: 791-798, 2003.
30. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45: 1524-1530, 1996.
31. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale, and standard data analysis methods. Drug Metab Rev 15: 153-171, 1984.
32. Thomaseth K, Pavan A, Pacini G, Ahrén B. Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice. Am J Physiol Endocrinol Metab 292: E1808-E1814, 2007.
33. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C. Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes 29: 979-990, 1980.
34. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88: 1772-1779, 2003.
35. Vilsbcheckentityøll T, Brock B, Perrild H, Levin K, Lervang H.-H. T, Kolendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, and Madsbad S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 25: 152-156, 2008.
36. Weiss R, Caprio S. Development of type 2 diabetes in children and adolescents. Minerva Med 97: 263-269, 2006.